Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the company’s reporting as a foreign private issuer and its formal company announcements on antibody-medicine operations, financial results, governance and share capital. Recent Form 6-K reports include interim financial information, DARZALEX® royalty-related sales disclosures from Johnson & Johnson, pipeline commentary for EPKINLY®, Rina-S® and petosemtamab, and updates incorporated by reference into Form S-8 registration statements.
The filing record also documents Danish-market disclosure matters, including major shareholder notifications, managerial transactions in shares and linked securities, amendments to the articles of association, and registered share capital reductions. These filings provide the formal record for Genmab’s capital structure, ownership notifications, governance documents and recurring biotechnology business disclosures.
Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025. One announcement describes a capital increase in Genmab resulting from employee warrant exercises. The other details transactions in Genmab shares and linked securities by managerial employees and their closely associated persons.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, making these announcements part of those share-based compensation plans’ disclosure record.
Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025. The report primarily forwards an attached company announcement describing a capital increase in Genmab resulting from the exercise of employee warrants. The filing also specifies that this 6-K is incorporated by reference into several existing Genmab Form S-8 registration statements covering employee equity compensation plans.
Genmab’s H1-25 6-K shows solid growth and an upgraded FY-25 outlook. Revenue climbed 19 % YoY to $1.64 bn on stronger DARZALEX (+22 % J&J sales), Kesimpta and EPKINLY. Royalty income rose 24 % to $1.38 bn, representing 84 % of total revenue. Operating profit increased 56 % to $548 m as costs grew only 6 %, expanding the margin to 33 %. Net profit reached $531 m.
Liquidity remains robust with $1.30 bn cash and $1.60 bn marketable securities; equity ratio is 82 %. Functional and presentation currency switched to USD on 1 Jan 25.
Revised 2025 guidance: revenue $3.5-3.7 bn (mid-point +$100 m), operating profit $1.055-1.405 bn (mid-point +$100 m); operating-expense range unchanged.
Operational highlights: sBLA filed for epcoritamab+R2 in r/r FL; Tivdak launched in Japan; Rina-S posted 50 % ORR in endometrial cancer; >40 epcoritamab abstracts presented. Workforce up to 2,639 FTEs.
Risks & negatives: TEPEZZA royalties -8 %; lower reimbursement revenue; ongoing Chugai patent suit and AbbVie trade-secret litigation; FX gains moderated after USD switch.
Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:
- A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
- An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025
The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.